X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs UNICHEM LAB - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA UNICHEM LAB NATCO PHARMA/
UNICHEM LAB
 
P/E (TTM) x 16.7 -64.1 - View Chart
P/BV x 18.0 0.7 2,513.7% View Chart
Dividend Yield % 0.6 2.4 26.9%  

Financials

 NATCO PHARMA   UNICHEM LAB
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
UNICHEM LAB
Mar-18
NATCO PHARMA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs877382 229.6%   
Low Rs424234 180.9%   
Sales per share (Unadj.) Rs223.4116.3 192.1%  
Earnings per share (Unadj.) Rs31.1-18.9 -164.2%  
Cash flow per share (Unadj.) Rs40.3-11.7 -343.0%  
Dividends per share (Unadj.) Rs5.005.00 100.0%  
Dividend yield (eoy) %0.81.6 47.4%  
Book value per share (Unadj.) Rs219.5381.0 57.6%  
Shares outstanding (eoy) m33.0770.34 47.0%   
Bonus/Rights/Conversions PABB-  
Price / Sales ratio x2.92.6 109.9%   
Avg P/E ratio x20.9-16.3 -128.6%  
P/CF ratio (eoy) x16.1-26.2 -61.5%  
Price / Book Value ratio x3.00.8 366.4%  
Dividend payout %16.1-26.4 -60.9%   
Avg Mkt Cap Rs m21,50421,668 99.2%   
No. of employees `000NA2.3 0.0%   
Total wages/salary Rs m1,1282,006 56.2%   
Avg. sales/employee Rs ThNM3,587.8-  
Avg. wages/employee Rs ThNM880.0-  
Avg. net profit/employee Rs ThNM-583.7-  
INCOME DATA
Net Sales Rs m7,3898,180 90.3%  
Other income Rs m167610 27.4%   
Total revenues Rs m7,5568,790 86.0%   
Gross profit Rs m1,793-1,320 -135.8%  
Depreciation Rs m304505 60.3%   
Interest Rs m36680 457.2%   
Profit before tax Rs m1,290-1,295 -99.6%   
Minority Interest Rs m460-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m30933 923.7%   
Profit after tax Rs m1,027-1,331 -77.2%  
Gross profit margin %24.3-16.1 -150.4%  
Effective tax rate %23.9-2.6 -927.6%   
Net profit margin %13.9-16.3 -85.5%  
BALANCE SHEET DATA
Current assets Rs m3,68123,318 15.8%   
Current liabilities Rs m3,1234,635 67.4%   
Net working cap to sales %7.6228.4 3.3%  
Current ratio x1.25.0 23.4%  
Inventory Days Days89122 73.5%  
Debtors Days Days59121 48.3%  
Net fixed assets Rs m7,6858,163 94.1%   
Share capital Rs m331141 235.0%   
"Free" reserves Rs m6,67026,660 25.0%   
Net worth Rs m7,25926,801 27.1%   
Long term debt Rs m9553 28,936.4%   
Total assets Rs m11,95731,890 37.5%  
Interest coverage x4.5-15.2 -29.8%   
Debt to equity ratio x0.10 106,838.3%  
Sales to assets ratio x0.60.3 240.9%   
Return on assets %11.7-3.9 -297.1%  
Return on equity %14.2-5.0 -285.0%  
Return on capital %20.7-4.5 -456.3%  
Exports to sales %39.40-   
Imports to sales %5.70-   
Exports (fob) Rs m2,908NA-   
Imports (cif) Rs m421NA-   
Fx inflow Rs m3,4454,356 79.1%   
Fx outflow Rs m7030-   
Net fx Rs m2,7434,356 63.0%   
CASH FLOW
From Operations Rs m1,440-1,123 -128.2%  
From Investments Rs m-1,08916,487 -6.6%  
From Financial Activity Rs m-353-8,811 4.0%  
Net Cashflow Rs m-16,552 -0.0%  

Share Holding

Indian Promoters % 52.0 50.1 103.9%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 15.1 51.9%  
FIIs % 16.6 3.0 554.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 31.7 82.0%  
Shareholders   25,395 20,176 125.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   TTK HEALTHCARE  SUVEN LIFE  CIPLA  ELDER PHARMA  VENUS REMEDIES  

Compare NATCO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY19); Net Profit Down 1479.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, UNICHEM LAB has posted a net profit of Rs 207 m (down 1479.6% YoY). Sales on the other hand came in at Rs 2 bn (down 35.9% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 21, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - ORCHID PHARMA LTD COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS